# Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone

> **NCT02023697** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 391 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Radium-223 dichloride (Xofigo, BAY88-8223)

## Key facts

- **NCT ID:** NCT02023697
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-10
- **Primary completion:** 2017-03-01
- **Final completion:** 2018-08-09
- **Target enrollment:** 391 (ACTUAL)
- **Last updated:** 2019-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02023697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02023697, "Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02023697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*